Currently approved PARP inhibitors used as a monotherapy are only effective in PC patients with mutations in the BRCA1/2 gene or HRR-related genes, but the incidence of these mutations is small with the rate of BRCA1/2 mutations of 8.8% in mCRPC patients (34). The gene discussed is BRCA1; the disease is pachyonychia congenita.